Chlamydia infection future or investigational therapies: Difference between revisions

Jump to navigation Jump to search
m (Changes made per Mahshid's request)
m (Bot: Removing from Primary care)
 
(One intermediate revision by one other user not shown)
Line 8: Line 8:
==References==
==References==
{{Reflist|2}}
{{Reflist|2}}
{{WikiDoc Help Menu}}
{{WikiDoc Sources}}


[[Category:Sexually transmitted diseases]]
[[Category:Sexually transmitted diseases]]
[[Category:Gynecology]]
[[Category:Gynecology]]
[[Category:FinalQCRequired]]
[[Category:FinalQCRequired]]
 
[[Category:Emergency medicine]]
{{WikiDoc Help Menu}}
[[Category:Disease]]
{{WikiDoc Sources}}
[[Category:Up-To-Date]]
[[Category:Infectious disease]]
[[Category:Urology]]

Latest revision as of 20:54, 29 July 2020

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Sexually transmitted diseases Main Page

Chlamydia infection Microchapters

Home

Patient Information

Overview

Historical Perspective

Pathophysiology

Causes

C. trachomatis
Other Chlamydiae

Differentiating Chlamydia Infection from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Ultrasound

Other Imaging Findings

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Chlamydia infection future or investigational therapies On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Chlamydia infection future or investigational therapies

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Chlamydia infection future or investigational therapies

CDC on Chlamydia infection future or investigational therapies

Chlamydia infection future or investigational therapies in the news

Blogs on Chlamydia infection future or investigational therapies

Directions to Hospitals Treating Chlamydia infection

Risk calculators and risk factors for Chlamydia infection future or investigational therapies

Future or Investigational Therapies

Recent phylogenetic studies have revealed that chlamydia shares a common ancestor with modern plants, and retains unusual plant-like traits (both genetically and physiologically). In particular, the enzyme L,L-diaminopimelate aminotransferase, which is related to lysine production in plants, is also linked with the construction of chlamydia's cell wall. The genetic encoding for the enzymes is remarkably similar in plants and chlamydia, demonstrating a close common ancestry.[1] This unexpected discovery may help scientists develop new treatment avenues: if scientists could find a safe and effective inhibitor of L,L-diaminopimelate aminotransferase, they might have a highly effective and extremely specific new antibiotic against chlamydia.

References

  1. McCoy AJ, Adams NE, Hudson AO, Gilvarg C, Leustek T, Maurelli AT (2006). "L,L-diaminopimelate aminotransferase, a trans-kingdom enzyme shared by Chlamydia and plants for synthesis of diaminopimelate/lysine". Proc. Natl. Acad. Sci. U.S.A. 103 (47): 17909–14. doi:10.1073/pnas.0608643103. PMID 17093042.


Template:WikiDoc Sources